Dr. Kiminobu Sugaya is a professor of medicine in Burnett School of Biomedical Science, College of Medicine, University of Central Florida (UCF) since 2004. He is a Director of Multidisciplinary Neuroscience Alliance of UCF and a Chair of Central Florida Chapter of Society for Neuroscience. He moved from Japan to Mayo Clinic, US as a post doc. in 1992 when he was a lecturer in Science University of Tokyo and he was promoted to an associate consultant in 1994. Then he moved to University of Illinois at Chicago as an assistant professor in 1997 and got promotied to an associate professor in 2002. He has been conducting stem cell researches to treat neurodegenerative diseases by the adult stem cells. He recently received National Honor Plaque of Panama for exceptional contribution to neuroscience based on his study on stem cell therapies for neurodegenerative diseases from the President of Panama. His publication regarding improvement of memory in the aged animal by stem cell transplantation was reported Washington Post, BBC, NBC, ABC and other media in all over the world. Dr. Sugaya is also a founder and chair of Progenicyte, which is a biotech company holding his 67 patent licenses. Among those are a revolutionary process of creating iPS (induced pluripotent stem) cells from a patient's own cells and a novel pharmacological approach to increase endogenous stem cells. With Dr. Sugaya's proprietary technologies covering all aspects of stem cell manipulations, Progenicyte is launching services to include: modified stem cell banking and a commercial product to increase cellular regeneration which fights against aging. Certain to be at the forefront of stem cell innovation.
Charles H Williams completed his PhD in 1968 and then a Post-Doctoral at the Institute for Enzyme Research with David E Green on mitochondrial studies. He also published with Henry A Lardy at the Enzyme Institute. He moved to Missouri as Associate Professor of Biochemistry and Assistant Professor of Medicine. He relocated to TTUHSC-El Paso in 1982, where MH research was his primary area of interest. He has published over 50 papers in refereed journals and has presented posters and lectures at many international events. He was a Full bright Fellow in Peru in 1970.
Luis Ulloa, PhD., is Associate Professor at the Department of Surgery, and a faculty member of the Center for Immunity and Inflammation at the New Jersey Medical School in the Rutgers University. Dr Ulloa has made significant contributions to science. He was among the original investigators describing the Smad in the TGF? signaling and their crosstalk with other immune signals such as the Interferon (Nature, 1999). This mechanism is now proposed to be critical in embryogenesis, oncogenesis and inflammatory bowel disorders. Dr Ulloa was also among the original investigators describing the anti-inflammatory potential of the vagus nerve, and its potential to control systemic inflammation in experimental trauma and sepsis. Dr Ulloa gor his first NIH grant as a pioner studying the immunological role of classical neurotransmitter and their signalling pathway controlling immune cells. Dr Ulloa published over 70 peer-review international articles in the most prestigious journals with over 11,000 total citations. Dr Ulloa has received numerous scientific awards such as the International Human Frontier Fellowship, the Rutgers University ‘Excellence in Research’ Award and the National Scientist Development Award of the American Heart Association. He is invited to write editorials and review articles in journals like Nature Reviews and Trends in Mol Med. His studies are funded by department of Defense, American Heart Association, and the NIH.
Neuromodulation, Drug Design, Host Response Immunology, Signal Transduction Therapeutics
Dr. Craig Russell always had a strong interest in science and in particular human biology, health and disease and the associated interventions. His undergraduate degree in Human Biology mapped onto this interest and included molecular and cellular biology, biochemistry and physiology modules among others, which would carry relevance in the physiology and pharmacology setting he progressed into. He further developed his knowledge and bolstered his interest in these fields during his PhD. During this period, formulation of oral liquid antihypertensives formed the initial stages of my project; here an understanding of the chemical and physical properties of drug molecules as well as drug action on a molecular level in a physiological setting was essential. In vitro and In vivo characterisation of developed formulations utilising cell and rodent based models paved the way for subsequent genomic investigations into intestinal transporter expression profiling using microarray technology and bioinformatics. Cell culture played a key role during a spin off project which he have been developing in parallel with the main path of research which has seen the isolation and characterisation of a novel primary cell line aimed at delineation of gustatory sensation.
Investigation of molecular mechanisms, imaging technologies, clinical therapeutics
Azad K. Kaushik has published two books [Molecular Immunobiology of Self-Reactivity (1992) and Comparative Immunoglobulin genetics (2014)] and over 87 research articles. He is on the editorial boards of several immunology journals and is a Consultant to various international organizations. He was recognized as The Esther Z. Greenberg Honors Chair in Biomedical Research, and Visiting Professor, Oklahoma Medical Research Foundation, USA, in 1998. He received BVSc&AH (Honors) in 1976 and MVSc (1978) from the Faculty of Veterinary Science, Hisar, Haryana, India; followed by Docteur es Science (DSc) in Immunology (1987) from the Pasteur Institute (University of Paris VII), Paris, France. He has been teaching Immunology at the University of Guelph since 1991.
Amongst many important discoveries, his team was the first to demonstrate that axon guidance molecules exacerbate brain function recovery after stroke through inducing axon shortening and active neuronal death. His team was also responsible for the seminal work showing that transcription factor E2F1 mediates the death of postmitotic neurons and that E2F1 regulates neuronal death in stroke brain. These studies revealed novel targets for the development of new drugs to promote brain function recovery. He published a series of high impact reports on molecular mechanisms of neuronal death (J Clin Invest, J Neurosci, JBC, Mol Cell Biol,) which were widely cited by other research groups. His team also made technological advancement in successfully constructing several hypoxia-inducible, neuron-specific adenoviral expression vectors, which have potential important clinical applications. The long-term goal of his research is aimed at reducing stroke-induced brain damage and speeding up recovery process through new scientific discoveries and technological innovations. The impact of his work is to reduce socio-economical burden to the society due to stroke-induced incapacity of brain function. Born in 1963, Professor Hou received his doctoral degree from the Faculty of Medicine, University of Glasgow in 1991. His doctoral study was supported by a full University of Glasgow Graduate Scholarship and a prestigious Overseas Research Student Award from the UK. After successfully completing his postdoctoral training at the Institute of Psychiatry, King’s College, University of London (1991-1993)?and the Department of Biochemistry, University of Bristol (1993-1996), Dr Hou was recruited by the National Research Council of Canada as Assistant Research Officer in May 1996. Since then, Dr Hou has risen to the rank of Group leader, Senior Research Officer (tenured position) and Adjunct Professor at the Department of Biochemistry, Immunology and Microbiology of the University of Ottawa to train doctoral and postdoctoral students. Dr Hou received many awards and research grants from research organizations of Canada, UK, and China. He was Principal Investigator and Project Leader of several Canadian National Research projects, a Canada-China Joint Health Initiative project and two Canada-British Council Joint Research Projects.
Investigation of molecular mechanisms, imaging technologies, clinical therapeutics
Cancer, Tumor Microenvironment, Immunotherapy, Virotherapy, Exosomes, RNA interference, Microbiology
Biochemistry, Medical Genetics